Drug Type Antibody drug conjugate (ADC) |
Synonyms- |
Target |
Mechanism DR5 inhibitors(Tumor necrosis factor receptor superfamily member 10B inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC39H67N5O7 |
InChIKeyDASWEROEPLKSEI-UIJRFTGLSA-N |
CAS Registry474645-27-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 1 | CN | 29 Nov 2023 | |
Non-Small Cell Lung Cancer | IND Application | CN | 07 Dec 2020 | |
Pancreatic Cancer | Preclinical | CN | 09 Apr 2023 | |
Pancreatic Cancer | Preclinical | CN | 09 Apr 2023 | |
Acute Lymphoblastic Leukemia | Preclinical | CN | 29 Apr 2021 | |
Acute Lymphoblastic Leukemia | Preclinical | CN | 29 Apr 2021 |